Lisata Therapeutics (NASDAQ:LSTA – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $15.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 455.56% from the stock’s current price.
Lisata Therapeutics Stock Performance
LSTA stock traded down $0.13 on Thursday, hitting $2.70. 3,910 shares of the company’s stock were exchanged, compared to its average volume of 12,983. Lisata Therapeutics has a 12-month low of $1.95 and a 12-month high of $4.53. The firm has a 50 day moving average price of $3.03 and a two-hundred day moving average price of $2.71. The stock has a market cap of $22.44 million, a P/E ratio of -1.05 and a beta of 1.04.
Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) last announced its earnings results on Thursday, February 29th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.20. Sell-side analysts expect that Lisata Therapeutics will post -3.08 earnings per share for the current fiscal year.
Institutional Trading of Lisata Therapeutics
About Lisata Therapeutics
Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.
Featured Stories
- Five stocks we like better than Lisata Therapeutics
- Compound Interest and Why It Matters When Investing
- Hasbro’s Management Made All the Right Calls This Quarter
- Bank Stocks – Best Bank Stocks to Invest In
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- What Are Trending Stocks? Trending Stocks Explained
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.